FDA Inspection
McGuff Pharmaceuticals, Inc.McGuff Pharmaceuticals, Inc. – FDA Inspection, Apr 28, 2025
Record Details
This FDA Inspection record concerns McGuff Pharmaceuticals, Inc., with an inspection on April 28, 2025, issued by the Los Angeles District Office, covering human drugs.
View Company Profile
ID · cb43831e-bcd5-477c-9ebc-e17f5a1a77de
Inspection Facts
Official Action Indicated (OAI)
Significant objectionable conditions were found and regulatory or administrative action is recommended.
- Inspection number
- 1268175
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
4- 21 CFR 211.113(b)Procedures for sterile drug products
- 21 CFR 211.22(d)Procedures not in writing, fully followed
- 21 CFR 211.67(b)Written procedures not established/followed
- 21 CFR 211.192No written record of investigation
Full citation text and observation details available on the Dashboard.
Other FDA inspections of McGuff Pharmaceuticals, Inc.
12| Date | Classification | Office | Project area |
|---|---|---|---|
| August 20, 2024 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| January 26, 2024 | VAI | Los Angeles District Office | New Drug Evaluation |
| November 22, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| March 26, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 2, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for McGuff Pharmaceuticals, Inc.
- FDA Inspection 1229677 - 2024-08-20
- FDA Inspection 1228033 - 2024-01-26
- FDA Inspection 1110847 - 2019-11-22
- FDA Inspection 1083919 - 2019-03-26
- FDA Inspection 1013240 - 2017-06-02
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.